You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
白雲山(00874.HK):奇星藥業收到藥品補充申請批件
格隆匯 03-24 18:51

格隆匯3月24日丨白雲山(00874.HK)公佈,公司獲悉,公司全資子公司廣州白雲山奇星藥業有限公司(“奇星藥業”)於2020年3月23日收到廣東省藥品監督管理局核准簽發的兩個品種(蛇膽陳皮散及蛇膽川貝散)的《藥品補充申請批件》。

蛇膽陳皮散的功能主治為:理氣化痰,祛風和胃。用於痰濁阻肺,胃失和降,咳嗽,嘔逆。奇星藥業於2002年8月16日取得蛇膽陳皮散的藥品註冊證,2018年12月向廣東省藥品監督管理局提出增加蛇膽陳皮散的直接接觸藥品包裝材料的補充申請。

目前國內蛇膽陳皮散的生產廠家還包括國藥集團馮了性(佛山)藥業有限公司、江西省芙蓉堂藥業股份有限公司等。根據米內網數據顯示,2018年蛇膽陳皮散在中國公立醫院和城市零售藥店的銷售額分別為人民幣969萬元和人民幣848萬元。2018年奇星藥業該藥品的銷售額為人民幣608萬元。

此外,蛇膽川貝散的功能主治為:清肺,止咳,除痰。用於肺熱咳嗽,痰多。奇星藥業於2002年8月16日取得蛇膽川貝散的藥品註冊證,2018年12月向廣東省藥品監督管理局提出增加蛇膽川貝散的直接接觸藥品包裝材料的補充申請。

目前國內蛇膽川貝散的生產廠家還包括國藥集團馮了性(佛山)藥業有限公司、華潤三九(黃石)藥業有限公司等。根據米內網數據顯示,2018年蛇膽川貝散在中國公立醫院和城市零售藥店的銷售額分別為人民幣1,248萬元和人民幣1,505萬元。2018年奇星藥業該藥品的銷售額為人民幣1,864萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account